Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study
Open Access
- 12 July 2022
- journal article
- research article
- Published by BMJ in BMJ Neurology Open
- Vol. 4 (2), e000309
- https://doi.org/10.1136/bmjno-2022-000309
Abstract
Objective To investigate features of Guillain-Barré syndrome (GBS) following SARS-CoV-2 vaccines and evaluate for a causal link between the two. Methods We captured cases of GBS after SARS-CoV-2 vaccination through a national, open-access, online surveillance system. For each case, the certainty of GBS was graded using the Brighton criteria, and the relationship to the vaccine was examined using modified WHO Causality Assessment criteria. We compared age distribution of cases with that of prepandemic GBS cases and clinical features with the International GBS Outcome Study (IGOS). Results Between 1 January and 30 June 2021, we received 67 reports of GBS following the ChAdOx1 vaccine (65 first doses) and three reports following the BNT162b2 vaccine (all first doses). The causal association with the vaccine was classified as probable for 56 (80%, all ChAdOx1), possible for 12 (17%, 10 ChAdOx1) and unlikely for two (3%, 1 ChAdOx1). A greater proportion of cases occurred in the 50–59 age group in comparison with prepandemic GBS. Most common clinical variants were sensorimotor GBS (n=55; 79%) and facial diplegia with paraesthesias (n=10; 14%). 10% (n=7/69) of patients reported an antecedent infection, compared with 77% (n=502/652) of the IGOS cohort (pInterpretation Most reports of GBS followed the first dose of ChAdOx1 vaccine. While our study cannot confirm or refute causation, this observation, together with the absence of alternative aetiologies, different than expected age distribution and the presence of unusual clinical features support a causal link. Clinicians and surveillance bodies should remain vigilant to the possibility of this very rare adverse event and its atypical variants.Keywords
Funding Information
- Medical Research Council (MR/V03 (UK MRC's Global Effort on COVID-19))
- National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections (NIHR200907)
- NIHR Global Health Research Group on Brain Infections (No. 17/63/110)
- National Institute for Health Research (ACF-2020-07-003)
This publication has 41 references indexed in Scilit:
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile rangeBMC Medical Research Methodology, 2014
- Guillain–Barré syndrome associated with normal or exaggerated tendon reflexesZeitschrift für Neurologie, 2011
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2011
- Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndromeNeurology, 2010
- The Epidemiology of Guillain-Barré Syndrome WorldwideNeuroepidemiology, 2008
- Under-Reporting of Adverse Drug ReactionsDrug Safety, 2006
- Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromesThe Lancet Infectious Diseases, 2001
- Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcomeAnnals of Neurology, 1998
- The spectrum of antecedent infections in Guillain-Barré syndromeNeurology, 1998
- CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHYThe Lancet, 1978